Published December 10, 2009 | Version public
Journal Article

Quality assurance of PASADENA hyperpolarization for ^(13)C biomolecules

  • 1. ROR icon Huntington Medical Research Institutes
  • 2. ROR icon California Institute of Technology
  • 3. ROR icon University of California, Santa Barbara
  • 4. ROR icon Saint Louis University

Abstract

Object Define MR quality assurance procedures for maximal PASADENA hyperpolarization of a biological ^(13)C molecular imaging reagent. Materials and methods An automated PASADENA polarizer and a parahydrogen generator were installed. ^(13)C enriched hydroxyethyl acrylate, 1^(-13)C, 2,3,3-d_3 (HEA), was converted to hyperpolarized hydroxyethyl propionate, 1^(-13)C, 2,3,3-d_3 (HEP) and fumaric acid, 1^(-13)C, 2,3-d_2 (FUM) to hyperpolarized succinic acid, 1^(-13)C, 2,3-d_2 (SUC), by reaction with parahydrogen and norbornadiene rhodium catalyst. Incremental optimization of successive steps in PASADENA was implemented. MR spectra and in vivo images of hyperpolarized ^(13)C imaging agents were acquired at 1.5 and 4.7 T. Results Application of quality assurance (QA) criteria resulted in incremental optimization of the individual steps in PASADENA implementation. Optimal hyperpolarization of HEP of P = 20% was achieved by calibration of the NMR unit of the polarizer (B_0 field strength ± 0.002 mT). Mean hyperpolarization of SUC, P = [15.3 ± 1.9]% (N = 16) in D _2O, and P = [12.8 ± 3.1]% (N = 12) in H_2O, was achieved every 5–8 min (range 13–20%). An in vivo ^(13)C succinate image of a rat was produced. Conclusion PASADENA spin hyperpolarization of SUC to 15.3% in average was demonstrated (37,400 fold signal enhancement at 4.7 T). The biological fate of 13C succinate, a normally occurring cellular intermediate, might be monitored with enhanced sensitivity.

Additional Information

© Springer 2009. 28 November 2007 Revised: 24 October 2008 Accepted: 5 November 2008. Published online: 6 December 2008. We thank the following for funding: NIH 1R21 CA118509 (PB), NCI 5R01CA122513 (BDR), NIH 1R01NS048589 (JBH, BDR), Rudi Schulte Research Institute (RSRI) (EYC, JBH), James G. Boswell Fellowship (PB, EYC), American Heart Association (PB), American Brain Tumor Association (PB), Tobacco Related Disease Research Program (PB), NARSAD (KH), Cancer Research and Prevention Foundation (EYC). We thank Dr. Daniel P. Weitekamp and Valerie A. Norton for assistance with the polarizer. We also thank Dr. William Opel for support of PASADENA program at HMRI, Dr. Scott Ross for providing convenient access to 14 T Varian high resolution solution NMR facility of Caltech. JBH thanks Drs. Peter Bachert and Wolfhard Semmler (German Cancer Research Center, DKFZ, Heidelberg, Germany) for PhD supervision. PB and BDR thank Drs. OskarAxelsson, Haukur Johannesson, Magnus Karlsson for advice and training with the parahydrogen polarizer, in Malmo and provided for this work under loan agreement between HMRI and GE Healthcare, established by Dr. Klaes Golman.

Additional details

Identifiers

Eprint ID
15546
Resolver ID
CaltechAUTHORS:20090902-074026235

Funding

NIH
1R21CA118509
NIH
5R01CA122513
NIH
1R01NS048589
Rudi Schulte Research Institute
James G. Boswell Foundation
American Heart Association
American Brain Tumor Association
California Tobacco-Related Disease Research Program
Cancer Research and Prevention Foundation
Dr. William Opel
Huntington Medical Research Institute (HMRI)
GE Healthcare

Dates

Created
2009-09-14
Created from EPrint's datestamp field
Updated
2021-11-08
Created from EPrint's last_modified field